[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-458922-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-458922-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","plasma-proteomic-profiling-of-neurodegenerative-proteins-in-autosomal-dominant-alzheimers-disease-with-psen1-mutations","Plasma Proteomic Profiling of Neurodegenerative Proteins in Autosomal Dominant Alzheimer’s Disease with PSEN1 Mutations","","Background: Alzheimer’s disease is characterized by amyloid-β (Aβ) plaque deposition, and autosomal dominant Alzheimer’s disease (ADAD) commonly arises from PSEN1 mutations that alter APP processing and increase Aβ production and aggregation. However, the effect of PSEN1 mutations on blood biomarker levels of neurodegeneration-related proteins is insufficiently studied. Method: NULISA/NULISAseq quantified 127 plasma proteins in PSEN1-mutant ADAD (n=6), sporadic AD (n=8), and cognitively unimpaired controls (n=7), using NPQ, Kruskal–Wallis and Wilcoxon tests, and Spearman correlation versus SIMOA. Results: High detectability and reproducibility were observed with significant correlations and group differences. Conclusion: Plasma proteomic targets can distinguish ADAD from sporadic AD, warranting larger validation cohorts.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/plasma-proteomic-profiling-of-neurodegenerative-proteins-in-autosomal-dominant-alzheimers-disease-with-psen1-mutations/458922/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/plasma-proteomic-profiling-of-neurodegenerative-proteins-in-autosomal-dominant-alzheimers-disease-with-psen1-mutations/458922.png","ImageObject",300,407,{"name":42,"@type":43},"A glass of water","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-08","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What study measured and in which participants?","Question",{"text":63,"@type":64},"The study used a NULISA-based assay to quantify 127 neurodegenerative proteins in plasma from PSEN1-mutant ADAD cases (n=6), sporadic AD (n=8), and cognitively unimpaired controls (n=7).","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How did the results compare between the NULISA assay and SIMOA-based measurements?",{"text":68,"@type":64},"NULISA showed robust correlations with SIMOA for key proteins including p-tau181, p-tau217, GFAP, NfL, and Aβ42, with Spearman coefficients ranging from 0.721 to 0.947.",{"name":70,"@type":61,"acceptedAnswer":71},"Which proteins differed significantly across diagnostic groups and between ADAD and sporadic AD?",{"text":72,"@type":64},"Total-tau (MAPT), p-tau181, p-tau217, and p-tau231 were among the most significantly different across groups, followed by NfL, NfH, CCL2, GFAP, and PDGFRB. Between ADAD and sporadic AD, targets such as NfH, CCL11, CHIT1, PDGFRB, PTN, and CNTN2 showed statistically significant differences.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},458922,1790754771,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":26,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":80,"read_time":97,"preview_page_count":26,"preview_urls":143},962090760832,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DOI: 10. 1002/alz70856_106861  \nBIOMARKERS  \nPOSTER PRESENTATION  \nBIOMARKERS (NON-NEUROIMAGING)  \nPlasma Proteomic Profiling of Neurodegenerative Proteins in Autosomal Dominant Alzheimer’s Disease with PSEN1 Mutations Relative to Sporadic Alzheimer’s Disease and Cognitively Unimpaired Controls  \nAlexandra M Izydorczak1  Marissa F Farinas2  Xuemei Zeng2   \nAnuradha Sehrawat 1  William E Klunk 1  Tharick A Pascoal 1  Ann D Cohen3 Victor L. Villemagne 1  Dana L Tudorascu 1  C. Elizabeth Shaaban 1   \nJennifer H Lingler3  Beth E. Snitz2  Eric E Abrahamson2  Sarah B Berman2 Julia K. Kofler2  Milos D. Ikonomovic4  M. Ilyas Kamboh3  Oscar L Lopez2 Thomas K Karikari 1  \n1 University of Pittsburgh, Pittsburgh, PA, USA  \n2 University of Pittsburgh School of Medicine, Pittsburgh, PA, USA  \n3 University of Pittsburgh Alzheimer’s Disease Research Center (ADRC), Pittsburgh, PA, USA  \n4 UPMC, Pittsburgh, PA, USA  \nCorrespondence  \nAlexandra M Izydorczak, University of Pittsburgh, Pittsburgh, PA, USA. [Email:](Email: AMI81@pitt.edu)[ AMI81@pitt.edu](Email: AMI81@pitt.edu)  \nAbstract  \nBackground: A major pathological hallmark of Alzheimer’s disease (AD) is plaque deposition of amyloid-β (Aβ) peptide which is cleaved from a larger Aβ precursor protein(APP). Oneof the most common causes of autosomal dominantAD (ADAD) are mutations in the PSEN1 gene, encoding a component of γ-secretase, which alter APP processing and increase the production and aggregation potential ofAβ. However, the impact of PSEN1 mutations on blood biomarker levels of neurodegeneration-related proteins is largely unexplored.  \nMethod: We applied a novel Nucleic Acid Linked Immuno-Sandwich Assay (NULISA), the NULISAseq CNS Disease Panel, to quantify 127 key neurodegenerative proteins in plasma samples from a cohort consisting of ADAD cases with PSEN1 mutations (n = 6), neuropathologically diagnosed sporadic AD (sAD; n = 8), and cognitively unimpaired controls (n = 7). Normalized protein quantification (NPQ) was used as a proxy for protein levels. Statistical comparisons were performed using the Kriskal-Wallis and Wilcoxon rank-sum tests. Spearman correlation was employed to evaluate the association between NULISA and Single Molecule Array (SIMOA)-based measurements.  \nResult: The NULISA had high detectability (95.5% ± 13. 6%) and reproducibility (median intra-plate coefficient ofvariation[CV]=6. 3%). NULISA and SIMOA correlated  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2025 The Alzheimer’s Association. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.  \nAlzheimer’s Dement. 2025;21(Suppl. 2):e106861.  \n[https://doi.org/10.1002/alz70856_106861](https://doi.org/10.1002/alz70856_106861)  \nwi[leyonlinelibrary.com/journal/alz](leyonlinelibrary.com/journal/alz)  \n1of2  \nBIOMARKERS  \nrobustly for p-tau181, p-tau217, GFAP, NfL, and Aβ42 (Spearman coefficients ρ range 0.721 to 0.947), but less so for Aβ40 (ρ=0.302). Total-tau (MAPT), p-tau181, p-tau217, and p-tau231 were among the proteins most significantly different across the sample groups (p values range 0.001 to 0.003), followed by NfL, NfH, CCL2, GFAP, and PDGFRB (p values range 0.005 to 0.046). Several targets, including NfH (p = 0.001), CCL11 (p = 0.013), CHIT1 (p = 0.021), PDGFRB (p = 0.029), PTN (p = 0.029), and CNTN2 (p = 0.043), showed statistically significant differences between ADAD and sAD.  \nConclusion: Proteomic profiling of key neurodegenerative proteins in plasma revealed significant differences among the sample groups and include identified targets that can distinguish ADAD from sAD. Further validation with larger cohorts is needed to confirm these findings.","cbCaifsnU4R3HNiY","https://ap.wps.com/l/cbCaifsnU4R3HNiY","pdf",98931,"English","# Abstract\n## Background\n## Method\n## Result\n## Conclusion","[{\"question\":\"What study measured and in which participants?\",\"answer\":\"The study used a NULISA-based assay to quantify 127 neurodegenerative proteins in plasma from PSEN1-mutant ADAD cases (n=6), sporadic AD (n=8), and cognitively unimpaired controls (n=7).\"},{\"question\":\"How did the results compare between the NULISA assay and SIMOA-based measurements?\",\"answer\":\"NULISA showed robust correlations with SIMOA for key proteins including p-tau181, p-tau217, GFAP, NfL, and Aβ42, with Spearman coefficients ranging from 0.721 to 0.947.\"},{\"question\":\"Which proteins differed significantly across diagnostic groups and between ADAD and sporadic AD?\",\"answer\":\"Total-tau (MAPT), p-tau181, p-tau217, and p-tau231 were among the most significantly different across groups, followed by NfL, NfH, CCL2, GFAP, and PDGFRB. Between ADAD and sporadic AD, targets such as NfH, CCL11, CHIT1, PDGFRB, PTN, and CNTN2 showed statistically significant differences.\"}]","Plasma Proteomic Profiling of Neurodegenerative Proteins in Autosomal Dominant Alzheimer’s Disease with PSEN1 Mutations | PDF",[144,148],{"page_no":22,"url":145,"width":146,"height":147},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/7471ed33b816f962609137aaebfda0f6.webp",983,1291,{"page_no":26,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-17/94b2e5297817ca798134ae3ffcd5ade8.webp",982,1290]